4. Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.
作者: Samir Gupta.;Lin Liu.;Joshua Demb.;Jiyue Qin.;Ashley Earles.;Mark Lamm.;Xinyi Huang.;Shailja C Shah.;Neetu Chawla.;Yi Le.;Tamra Burns Loeb.;Jason A Dominitz.;Douglas J Robertson.;Nancy L Schoenborn.;Audrey H Calderwood.;Theodore R Levin.;Benjamin J Seligman.;Folasade P May.
来源: JAMA. 2026年
Colorectal cancer (CRC) risk among older adults with prior adenoma is uncertain.
10. Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy.
作者: Samuel Luebbe.;Allan D Sniderman.;Andrew E Moran.;John T Wilkins.;Ciaran N Kohli-Lynch.
来源: JAMA. 2026年
Apolipoprotein B (apoB) is a superior marker of residual atherosclerotic cardiovascular disease risk in patients treated with lipid-lowering therapy (LLT) compared with low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). The cost-effectiveness of LDL-C, non-HDL-C, and apoB goals has not been established.
20. Discontinuation of Levothyroxine in Adults Aged 60 Years or Older.
作者: Janneke Ravensberg.;Jacobijn Gussekloo.;Saskia Le Cessie.;Olaf M Dekkers.;Simon P Mooijaart.;Rosalinde K E Poortvliet.
来源: JAMA. 2026年
Many adults aged 60 years or older take the thyroid hormone levothyroxine, which is generally continued for life. However, it is uncertain whether long-term continuation is always necessary.
|